EnteroMedics Inc  

(Public, NASDAQ:ETRM)   Watch this stock  
Find more results for Catherine Lea�
1.50
+0.03 (2.40%)
Real-time:   12:41PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.41 - 1.50
52 week 1.01 - 2.66
Open 1.47
Vol / Avg. 372,393.00/773,172.00
Mkt cap 100.24M
P/E     -
Div/yield     -
EPS -0.43
Shares 68.89M
Beta 2.21
Inst. own 29%
Oct 29, 2014
Q3 2014 EnteroMedics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Aug 14, 2014
EnteroMedics Inc at Canaccord Genuity Growth Conference
Aug 7, 2014
Q2 2014 EnteroMedics Inc Earnings Call - Webcast
Aug 7, 2014
Q2 2014 ENTEROMEDICS INC Earnings Release
Jun 17, 2014
ENTEROMEDICS INC Advisory Committee Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -115.81% -98.24%
Return on average equity -188.61% -194.18%
Employees 27 -
CDP Score - -

Address

2800 Patton Road
ST. PAUL, MN 55113
United States - Map
+1-651-6343003 (Phone)
+1-651-6343212 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

EnteroMedics Inc. (EnteroMedics) is a development- stage medical device company. The Company focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company�s neuroblocking technology, which it refers to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company�s initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. As of December 31, 2011, the Company�s enrollment and implantation in randomized, double-blind, parallel-group, multicenter pivotal clinical trial (the ReCharge trial), was completed in 233 patients at 10 centers.

Officers and directors

Mark B. Knudson Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Gregory S. Lea Chief Financial Officer, Chief Operating Officer, Senior Vice President
Age: 61
Bio & Compensation  - Reuters
Adrianus Donders Senior Vice President - Research and Advanced Development
Age: 60
Bio & Compensation  - Reuters
Mark Bullivant Vice President - Marketing
Bio & Compensation  - Reuters
Katherine S. Tweden Ph.D. Vice President - Clinical and Regulatory
Age: 53
Bio & Compensation  - Reuters
Anthony P. Jansz Director
Age: 53
Bio & Compensation  - Reuters
Luke B. Evnin Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
Catherine J. Friedman Independent Director
Age: 53
Bio & Compensation  - Reuters
Carl S. Goldfischer M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Bobby I. Griffin Independent Director
Age: 76
Bio & Compensation  - Reuters